P1NP Unit Converter
P1NP Unit Converter
Convert procollagen type I N-terminal propeptide between µg/L, ng/mL and ng/L — the reference marker of bone formation, read as a change from baseline on one assay rather than as a single number.
P1NP converter
Mass ladder onlyP1NP 45 µg/L, adult male
The conversion — a mass ladder, with no molar unit
1 µg/L = 1,000 ng/L
ng/L = µg/L × 1,000
- µg/L = ng/mL
- a microgram per litre and a nanogram per millilitre are the same concentration, so no arithmetic is needed between them. Almost every P1NP report uses one of these two
- ng/L
- a thousandfold smaller unit, seen occasionally. A P1NP of 45 µg/L is 45,000 ng/L — if a P1NP arrives in the tens of thousands, this is why
- no molar unit, deliberately
- P1NP is a propeptide whose assays measure either the intact trimeric form or that plus its monomeric degradation products, at different proportions. There is no single molecular weight that applies to what is measured, so this converter offers a mass ladder only
- <b>intact P1NP against total P1NP</b>
- the distinction that actually changes the number. An intact assay measures the trimeric propeptide; a total assay measures the trimer plus monomeric fragments. The monomers are renally cleared, so the gap between the two widens as renal function falls. Reference intervals, treatment thresholds and serial results all belong to one assay type — never mix them
Worked example
P1NP 45 µg/L, adult male
45 µg/L = 45.0 ng/mL — the same concentration written the other way
45 × 1,000 = 45,000 ng/L, the same number at the smaller scale
45.0 µg/L sits inside Mayo's adult male interval of 22–87 µg/L for their intact-P1NP radioimmunoassay
Now put it to work: if this were a baseline before starting an oral bisphosphonate, the result to look for at three to six months is a substantial fall — Mayo quote a change of 21% or more from baseline as an adequate response on their assay
A P1NP that has not fallen is a question about adherence and absorption before it is a question about the drug
The recommended pair, and what a divergence between them means
| Marker | Side of the cycle | What a fall means | What a rise means |
|---|---|---|---|
| P1NP | Formation — cleaved from procollagen as osteoblasts lay down matrix | Antiresorptive working, or formation suppressed (glucocorticoids) | High turnover, an anabolic agent such as teriparatide, fracture healing, Paget’s disease |
| CTX | Resorption — released as osteoclasts degrade collagen | Antiresorptive working | High turnover, untreated postmenopausal bone loss, recent fracture |
| Both falling together | Coupled remodelling | The expected pattern on a bisphosphonate or denosumab | — |
| P1NP rising while CTX stays low | Uncoupled | — | The pattern of an anabolic agent: teriparatide and abaloparatide raise formation first |
What changes a P1NP other than bone
| Factor | Effect | Note |
|---|---|---|
| Renal impairment | Raises it — less than it raises CTX, and mostly on total-P1NP assays | The monomeric fragments a total assay detects are renally cleared. An intact-P1NP assay is less affected, which is one argument for using it in chronic kidney disease |
| Recent fracture | Raises it for months | Do not take a treatment baseline soon after a fracture |
| Food and time of day | Much less variable than CTX | P1NP has little circadian variation and is not suppressed by feeding, so it does not require a fasting morning sample — a practical advantage over CTX |
| Severe liver disease | Can raise it | P1NP is cleared by hepatic endothelial cells |
| Growth | High in children and adolescents | Mayo have not established paediatric reference values for this assay |
Using P1NP to monitor osteoporosis treatment
| Stage | What to do |
|---|---|
| Before starting | Measure a baseline on the assay the laboratory will use for follow-up, and not within a few months of a fracture |
| Three to six months after starting an antiresorptive | Repeat on the same assay. A substantial fall — Mayo quote 21% or more from baseline on their method, and other assays have their own least significant change — indicates an adequate response |
| If it has not fallen | Ask about adherence and about how an oral bisphosphonate is being taken: fasting, upright, with plain water, nothing else for 30 minutes. Then consider malabsorption and secondary causes of high turnover |
| On an anabolic agent | Expect P1NP to rise early. A rise confirms the drug is working; it is the opposite of what an antiresorptive should do |
| During a drug holiday | A return of P1NP towards the pretreatment value suggests the antiresorptive effect is wearing off |
The formation marker, and the assay it belongs to
Procollagen type I N-terminal propeptide — P1NP — is cleaved from the end of the procollagen molecule as osteoblasts assemble new type I collagen, so its concentration in serum reports the rate at which bone matrix is being laid down. It is the reference marker of bone formation recommended by the International Osteoporosis Foundation and the IFCC, paired with CTX as the reference marker of resorption. Reports are in micrograms per litre or the identical nanograms per millilitre, with nanograms per litre — a thousandfold smaller — appearing occasionally. There is no molar unit: the assays measure a propeptide in more than one molecular form, so no single molecular weight applies.
That last point matters more than it sounds. Two kinds of P1NP assay are in use. An intact assay measures the trimeric propeptide only; a total assay measures the trimer together with the monomeric fragments it degrades into. The monomers are cleared by the kidney, so the two assays diverge as renal function falls, and they diverge in the direction that matters — total P1NP rises in chronic kidney disease while intact P1NP is much less affected. The reference intervals on this page belong to an intact-P1NP radioimmunoassay. Most published monitoring data, and most automated laboratory platforms, use total P1NP. A P1NP is therefore read against its own assay’s interval, and a series of results must stay on one method.
P1NP has one large practical advantage over CTX. Bone resorption has a marked circadian rhythm and CTX is suppressed sharply by eating, which is why a CTX has to be taken fasting and before 10 a.m. to mean anything. P1NP varies much less through the day and is not meaningfully suppressed by food, so it can be taken in an ordinary clinic appointment. Renal impairment still raises it, and a recent fracture raises it for months, so both are checked before a result is read as bone turnover.
The use of the test is monitoring rather than diagnosis. Osteoporosis is diagnosed on bone mineral density and fracture history; no turnover marker makes or excludes that diagnosis, and a patient with severe osteoporosis can have an unremarkable P1NP. What P1NP does is show, within three to six months, whether a treatment is reaching the skeleton — long before a repeat DXA scan could. On an antiresorptive the expected change is a substantial fall, and a fall of that size is good evidence that an oral bisphosphonate is being taken correctly and absorbed, which is not a trivial question given how demanding the dosing instructions are. On an anabolic agent such as teriparatide the expected change is the opposite — an early rise in P1NP, with CTX following later — so the direction of the change identifies the class of drug as well as confirming that it is working.
Frequently asked questions
How do you convert P1NP from µg/L to ng/mL?
You do not need to: they are the same number. A P1NP of 45 µg/L is 45.0 ng/mL. The only real conversion on this page is to nanograms per litre, which are a thousandfold smaller — 45 µg/L is 45,000 ng/L. There is no molar unit for P1NP, because the assays measure the propeptide in more than one molecular form and no single molecular weight applies.
What is the difference between intact P1NP and total P1NP?
An intact assay measures the trimeric propeptide only; a total assay measures the trimer plus its monomeric degradation fragments. The monomers are renally cleared, so total P1NP rises in chronic kidney disease while intact P1NP is much less affected, and the two give different numbers in the same patient. Reference intervals and serial results belong to one assay type — check which your laboratory runs before comparing anything.
Does P1NP need a fasting morning sample like CTX?
No, and that is one of its advantages. P1NP has little circadian variation and is not meaningfully suppressed by eating, so it can be taken at an ordinary clinic appointment. CTX, by contrast, falls sharply after a meal and peaks in the early hours, so it must be sampled fasting and before 10 a.m. to be interpretable.
How much should P1NP fall on treatment?
Substantially, and within three to six months. Mayo quote a fall of 21% or more from baseline on their intact-P1NP assay as an adequate response to antiresorptive treatment; other assays have their own least significant change, so the threshold belongs to the method. A P1NP that has not moved is a reason to ask about adherence and about how an oral bisphosphonate is being taken before concluding that the drug has failed.
Can P1NP diagnose osteoporosis?
No. Osteoporosis is diagnosed from bone mineral density measured by DXA together with fracture history, and a turnover marker neither makes nor excludes that diagnosis. P1NP reports the rate at which bone is being formed, which is a different quantity from how much bone there is. Its role is in monitoring whether treatment is working.
Related calculators
References
- Mayo Clinic Laboratories. Test ID: PINP — Procollagen I Intact N-Terminal, Serum. Reference values: adult male 22–87 mcg/L, premenopausal female 19–83 mcg/L, postmenopausal female 16–96 mcg/L; radioimmunoassay; a change of 21% or more from baseline at 3–6 months indicates an adequate therapeutic response.
- Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. doi:10.1007/s00198-010-1501-1
- Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908–923. doi:10.1016/S2213-8587(17)30184-5
- Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem. 2012;45(12):920–927. doi:10.1016/j.clinbiochem.2012.03.023
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.